Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Clinical trial NCT06714617 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT06714617
Sponsor: SystImmune Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Breast Cancer Stage III HER2-positive Metastatic Breast Cancer Unresectable Breast Carcinoma Her2-Positive HER2 Gene Mutation Gastroesophageal-junction Cancer Non Small Cell Lung Cancer Endometrial Neoplasms Peritoneal Cancer Fallopian Tube Cancer Ovarian Cancer Urothelial Carcinoma Bladder

Start date: 2025-04-10
Primary completion: 2027-09-01
Enrollment: 120

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.